(ANIP) ANI Pharmaceuticals - Ratings and Ratios
Prescription, Specialty, Generic, Liquid, Capsules
ANIP EPS (Earnings per Share)
ANIP Revenue
Description: ANIP ANI Pharmaceuticals
ANI Pharmaceuticals Inc (NASDAQ:ANIP) is a US-based pharmaceutical company. As a player in the pharmaceuticals industry, the companys performance is influenced by factors such as R&D pipeline, regulatory approvals, and market competition.
The quarterly Income Tax Expense data point is a crucial aspect of the companys financials, as it directly impacts the net income. A thorough analysis of this metric can reveal trends in the companys tax strategy and potential implications for future profitability. Key drivers to watch include changes in tax rates, adjustments to tax provisions, and the impact of international operations on tax liabilities.
To evaluate ANIPs performance, key performance indicators (KPIs) such as revenue growth, gross margin, and operating expenses as a percentage of revenue are essential. Additionally, metrics like Return on Equity (RoE) and Forward Price-to-Earnings (P/E) ratio provide insights into the companys profitability and valuation. Currently, ANIPs RoE is negative, indicating potential challenges in generating profits for shareholders.
Economic drivers that impact the pharmaceutical industry, such as government policies on healthcare, patent expirations, and the introduction of generics, can significantly influence ANIPs stock performance. The companys market capitalization and trading volume are also important indicators of its market presence and liquidity.
A comprehensive analysis of ANIPs financials, industry trends, and competitive landscape is necessary to identify potential trading opportunities. By examining the companys quarterly Income Tax Expense in conjunction with other fundamental and technical indicators, investors can gain a more nuanced understanding of the stocks potential for growth or decline.
ANIP Stock Overview
| Market Cap in USD | 2,119m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2000-05-05 |
ANIP Stock Ratings
| Growth Rating | 90.4% |
| Fundamental | 54.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 34.0% |
| Analyst Rating | 4.33 of 5 |
ANIP Dividends
Currently no dividends paidANIP Growth Ratios
| Growth Correlation 3m | 85.3% |
| Growth Correlation 12m | 76.6% |
| Growth Correlation 5y | 88.2% |
| CAGR 5y | 42.24% |
| CAGR/Max DD 3y | 1.65 |
| CAGR/Mean DD 3y | 4.61 |
| Sharpe Ratio 12m | 0.98 |
| Alpha | 0.12 |
| Beta | 0.590 |
| Volatility | 33.46% |
| Current Volume | 432.1k |
| Average Volume 20d | 414k |
| Stop Loss | 92.4 (-3.1%) |
| Signal | -0.23 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-11.0m TTM) > 0 and > 6% of Revenue (6% = 44.8m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA -1.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 48.94% (prev 77.03%; Δ -28.09pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 139.1m > Net Income -11.0m (YES >=105%, WARN >=100%) |
| Net Debt (102.3m) to EBITDA (94.4m) ratio: 1.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (20.3m) change vs 12m ago 5.11% (target <= -2.0% for YES) |
| Gross Margin 57.95% (prev 53.07%; Δ 4.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 66.03% (prev 58.53%; Δ 7.50pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.40 (EBITDA TTM 94.4m / Interest Expense TTM 24.7m) >= 6 (WARN >= 3) |
Altman Z'' 1.57
| (A) 0.27 = (Total Current Assets 602.6m - Total Current Liabilities 236.8m) / Total Assets 1.34b |
| (B) -0.06 = Retained Earnings (Balance) -76.9m / Total Assets 1.34b |
| (C) 0.01 = EBIT TTM 9.93m / Avg Total Assets 1.13b |
| (D) -0.08 = Book Value of Equity -73.5m / Total Liabilities 906.2m |
| Total Rating: 1.57 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 54.22
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 4.41% = 2.21 |
| 3. FCF Margin 14.90% = 3.73 |
| 4. Debt/Equity 1.42 = 1.57 |
| 5. Debt/Ebitda 6.58 = -2.50 |
| 6. ROIC - WACC (= -5.82)% = -7.27 |
| 7. RoE -2.54% = -0.42 |
| 8. Rev. Trend 97.73% = 7.33 |
| 9. EPS Trend -8.29% = -0.41 |
What is the price of ANIP shares?
Over the past week, the price has changed by -2.16%, over one month by +6.29%, over three months by +50.52% and over the past year by +58.77%.
Is ANI Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANIP is around 120.66 USD . This means that ANIP is currently undervalued and has a potential upside of +26.53% (Margin of Safety).
Is ANIP a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANIP price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 99 | 3.8% |
| Analysts Target Price | 99 | 3.8% |
| ValueRay Target Price | 132.2 | 38.7% |
Last update: 2025-09-13 05:00
ANIP Fundamental Data Overview
CCE Cash And Equivalents = 217.8m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 12.4224
P/S = 2.8355
P/B = 4.9028
P/EG = 1.06
Beta = 0.633
Revenue TTM = 747.4m USD
EBIT TTM = 9.93m USD
EBITDA TTM = 94.4m USD
Long Term Debt = 608.3m USD (from longTermDebt, last quarter)
Short Term Debt = 13.2m USD (from shortTermDebt, last quarter)
Debt = 621.6m USD (Calculated: Short Term 13.2m + Long Term 608.3m)
Net Debt = 102.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.52b USD (2.12b + Debt 621.6m - CCE 217.8m)
Interest Coverage Ratio = 0.40 (Ebit TTM 9.93m / Interest Expense TTM 24.7m)
FCF Yield = 4.41% (FCF TTM 111.4m / Enterprise Value 2.52b)
FCF Margin = 14.90% (FCF TTM 111.4m / Revenue TTM 747.4m)
Net Margin = -1.48% (Net Income TTM -11.0m / Revenue TTM 747.4m)
Gross Margin = 57.95% ((Revenue TTM 747.4m - Cost of Revenue TTM 314.3m) / Revenue TTM)
Tobins Q-Ratio = -34.30 (set to none) (Enterprise Value 2.52b / Book Value Of Equity -73.5m)
Interest Expense / Debt = 1.32% (Interest Expense 8.22m / Debt 621.6m)
Taxrate = 18.77% (1.98m / 10.5m)
NOPAT = 8.06m (EBIT 9.93m * (1 - 18.77%))
Current Ratio = 2.54 (Total Current Assets 602.6m / Total Current Liabilities 236.8m)
Debt / Equity = 1.42 (Debt 621.6m / last Quarter total Stockholder Equity 436.8m)
Debt / EBITDA = 6.58 (Net Debt 102.3m / EBITDA 94.4m)
Debt / FCF = 5.58 (Debt 621.6m / FCF TTM 111.4m)
Total Stockholder Equity = 434.9m (last 4 quarters mean)
RoA = -0.82% (Net Income -11.0m, Total Assets 1.34b )
RoE = -2.54% (Net Income TTM -11.0m / Total Stockholder Equity 434.9m)
RoCE = 0.95% (Ebit 9.93m / (Equity 434.9m + L.T.Debt 608.3m))
RoIC = 0.78% (NOPAT 8.06m / Invested Capital 1.04b)
WACC = 6.59% (E(2.12b)/V(2.74b) * Re(8.21%)) + (D(621.6m)/V(2.74b) * Rd(1.32%) * (1-Tc(0.19)))
Shares Correlation 3-Years: 93.94 | Cagr: 2.02%
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 69.72% ; FCFE base≈104.5m ; Y1≈68.6m ; Y5≈31.4m
Fair Price DCF = 27.65 (DCF Value 599.7m / Shares Outstanding 21.7m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -8.29 | EPS CAGR: 45.65% | SUE: 0.83 | # QB: 0
Revenue Correlation: 97.73 | Revenue CAGR: 39.98% | SUE: N/A | # QB: None
Additional Sources for ANIP Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle